The role of inflammation in anxiety and depression in the European U-BIOPRED asthma cohorts

•Severe asthma patients are at higher risk of anxiety and depression.•Depression in asthma was associated with IL6, MCP1, CCL18 level, and CCL17, whereas anxiety was associated with CCL17 only.•Inflammatory mechanism may underlie this comorbidity. Growing evidence indicates high comorbid anxiety and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain, behavior, and immunity behavior, and immunity, 2023-07, Vol.111, p.249-258
Hauptverfasser: Hou, Ruihua, Ye, Gang, Cheng, Xiaojing, Shaw, Dominick E., Bakke, Per S., Caruso, Massimo, Dahlen, Barbro, Dahlen, Sven-Erik, Fowler, Stephen J., Horváth, Ildikó, Howarth, Peter, Krug, Norbert, Montuschi, Paolo, Sanak, Marek, Sandström, Thomas, Auffray, Charles, De Meulder, Bertrand, Sousa, Ana R., Adcock, Ian M., Fan Chung, Kian, Sterk, Peter J., Skipp, Paul J., Schofield, James, Djukanović, Ratko
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Severe asthma patients are at higher risk of anxiety and depression.•Depression in asthma was associated with IL6, MCP1, CCL18 level, and CCL17, whereas anxiety was associated with CCL17 only.•Inflammatory mechanism may underlie this comorbidity. Growing evidence indicates high comorbid anxiety and depression in patients with asthma. However, the mechanisms underlying this comorbid condition remain unclear. The aim of this study was to investigate the role of inflammation in comorbid anxiety and depression in three asthma patient cohorts of the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) project. U-BIOPRED was conducted by a European Union consortium of 16 academic institutions in 11 European countries. A subset dataset from subjects with valid anxiety and depression measures and a large blood biomarker dataset were analysed, including 198 non-smoking patients with severe asthma (SAn), 65 smoking patients with severe asthma (SAs), 61 non-smoking patients with mild-to-moderate asthma (MMA), and 20 healthy non-smokers (HC). The Hospital Anxiety and Depression Scale was used to measure anxiety and depression and a series of inflammatory markers were analysed by the SomaScan v3 platform (SomaLogic, Boulder, Colo). ANOVA and the Kruskal-Wallis test were used for multiple-group comparisons as appropriate. There were significant group effects on anxiety and depression among the four cohort groups (p 
ISSN:0889-1591
1090-2139
1090-2139
DOI:10.1016/j.bbi.2023.04.011